Key Highlights from VolitionRx Limited (VNRX) Special Shareholder Meeting (March 31, 2026)

VolitionRx Limited (NYSE: VNRX), a company specializing in in vitro and in vivo diagnostic substances, held a special meeting of stockholders on March 31, 2026, in London, UK. This meeting contained several important developments that investors should closely monitor, as they could have a direct impact on the company’s share price and future direction.

1. Proposals Voted Upon

• Proposal 1: Approval of the issuance of additional shares of common stock to Lind Global Asset Management XII LLC, exceeding 20% of outstanding shares. This was necessary for compliance with NYSE American Rule 713.
  Voting Results:
  • Votes For: 44,152,648
  • Votes Against: 14,095,382
  • Abstained: 1,114,276
  • Broker Non-Votes: 21,146,445
• Proposal 2: Approval of an amendment to the company’s Second Amended and Restated Certificate of Incorporation to authorize a reverse stock split of common stock in a ratio between 1-for-5 and 1-for-20, as determined by the Board.
  Voting Results:
  • Votes For: 62,838,654
  • Votes Against: 16,451,299
  • Abstained: 1,114,798

2. Important Shareholder Information & Price Sensitivity

• Large Share Issuance to Lind Global Asset Management XII LLC:
  The approval allows VolitionRx to issue a substantial number of new shares to Lind Global Asset Management XII LLC. This could lead to dilution of existing shareholders, which is often viewed as negative by the market unless the capital raised is used to drive significant growth or value creation.
• Reverse Stock Split Authorization:
  The Board now has the authority to execute a reverse stock split at a ratio between 1-for-5 and 1-for-20. Reverse splits are typically enacted to increase the share price and maintain exchange listing requirements, but can sometimes be interpreted as a signal of financial distress or underperformance. This move could materially impact the trading dynamics and perception of VolitionRx shares.
• Shareholder Participation:
  Out of 135,565,325 shares outstanding as of the record date, 80,508,751 shares were present in person or by proxy, indicating healthy shareholder engagement for these critical votes.

3. Corporate Details

• Company Name: VolitionRx Limited
• Address: 1489 West Warm Springs Road, Suite 110, Henderson, NV 89014
• Trading Symbol: VNRX
• Exchange: NYSE American
• Industry: Life Sciences – Diagnostic Substances
• CEO & President: Cameron Reynolds (signed the report)

4. Analysis: Potential Impact on Share Price

Both proposals are price sensitive and could significantly impact VNRX’s valuation:

• Share dilution risk: The approval of new share issuance may pressure the stock price if investors fear dilution outweighs potential benefits from the capital raised.
• Reverse stock split: While reverse splits can help maintain listing and improve optics, they often follow prolonged price declines and may be viewed negatively unless accompanied by positive business developments.
• Strategic partnership financing: The deal with Lind Global Asset Management XII LLC may be part of a broader strategic financing plan. Investors should monitor how these funds are deployed.

Conclusion

Investors should closely track VolitionRx’s next steps, especially regarding the timing and ratio of any reverse stock split and the specifics of the share issuance to Lind Global Asset Management XII LLC. These actions could lead to increased volatility and potential revaluation of VNRX shares in the near term.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with financial advisors before making any investment decisions. Events described herein may impact the share price of VolitionRx Limited (VNRX), but there is no guarantee of specific outcomes.

View VOLITIONRX LTD Historical chart here